SoftOx Solutions AS (SOFTX) - Total Liabilities

Latest as of September 2025: Nkr17.26 Million NOK ≈ $1.82 Million USD

Based on the latest financial reports, SoftOx Solutions AS (SOFTX) has total liabilities worth Nkr17.26 Million NOK (≈ $1.82 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SoftOx Solutions AS equity growth rate to track the company's year-over-year net asset growth rate.

SoftOx Solutions AS - Total Liabilities Trend (2016–2024)

This chart illustrates how SoftOx Solutions AS's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does SoftOx Solutions AS generate to measure how efficiently the company converts operating cash flow to free cash.

SoftOx Solutions AS Competitors by Total Liabilities

The table below lists competitors of SoftOx Solutions AS ranked by their total liabilities.

Company Country Total Liabilities
Altech Chemicals Ltd
F:A3Y
Germany €16.45 Million
YOC AG
F:YOC
Germany €13.25 Million
OD6 Metals Ltd
AU:OD6
Australia AU$1.12 Million
Xu Yuan Packaging Technology Co Ltd
TWO:8421
Taiwan NT$1.15 Billion
Alankit Limited
NSE:ALANKIT
India Rs1.15 Billion
Flagship Investments Ltd
AU:FSI
Australia AU$21.28 Million
Inalways
TWO:5398
Taiwan NT$70.17 Million
Petratherm Ltd
AU:PTR
Australia AU$466.42K

Liability Composition Analysis (2016–2024)

This chart breaks down SoftOx Solutions AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is SoftOx Solutions AS worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.16 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.17 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.15 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SoftOx Solutions AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SoftOx Solutions AS (2016–2024)

The table below shows the annual total liabilities of SoftOx Solutions AS from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 Nkr25.96 Million
≈ $2.73 Million
-72.64%
2023-12-31 Nkr94.87 Million
≈ $9.98 Million
+53.45%
2022-12-31 Nkr61.83 Million
≈ $6.51 Million
+237.34%
2021-12-31 Nkr18.33 Million
≈ $1.93 Million
+65.23%
2020-12-31 Nkr11.09 Million
≈ $1.17 Million
-40.03%
2019-12-31 Nkr18.50 Million
≈ $1.95 Million
+105.86%
2018-12-31 Nkr8.98 Million
≈ $945.45K
+114.38%
2017-12-31 Nkr4.19 Million
≈ $441.01K
-34.30%
2016-12-31 Nkr6.38 Million
≈ $671.23K
--

About SoftOx Solutions AS

OL:SOFTX Norway Biotechnology
Market Cap
$23.70 Million
Nkr225.18 Million NOK
Market Cap Rank
#24578 Global
#227 in Norway
Share Price
Nkr0.09
Change (1 day)
-2.28%
52-Week Range
Nkr0.05 - Nkr0.16
All Time High
Nkr112.00
About

SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that develops antimicrobials products for infection prevention and treatment in Norway. The company develops SoftOx Inhalation Solution, an inhalation solution that is phase II clinical trial for the treatment of ventilator associated pneumonia and other airway infections. It also developing p… Read more